Cryoport Q2 2026 Earnings: Familiar Story, Same Unprofitability

What happened

Cryoport’s Q2 2026 call reiterated the management narrative of services growth and gross margin improvement, yet the company still operates at a net loss. The deep integration into cell and gene therapy logistics is promising, but translating that into consistent profitability remains elusive after years of investment. Recent restructuring, including the CRYOPDP divestiture, has reduced cash burn, but the core business has yet to demonstrate operating leverage at scale. The stock price has recovered from lows, suggesting the market is betting on a turnaround that the fundamentals have not yet justified. Without a clear inflection in free cash flow, Cryoport remains a speculative play on the CGT boom.

Implication

The investment thesis hinges on Cryoport converting its embedded position in the CGT ecosystem into durable earnings, but that conversion has been delayed by overbuilt capacity and sluggish therapy approvals. The $421 million cash position provides a multi-year runway, yet past impairments and negative FCF raise concerns about capital allocation discipline. For value-conscious investors, entry makes sense only when adjusted EBITDA is sustainably positive and the market offers a margin of safety—neither condition is met today. Monitoring the pace of Phase III trial conversions and the DHL partnership’s contribution is crucial, but for now, the risk-reward is tilted against early commitment. A potential buy signal would be consecutive quarters of positive operating cash flow alongside mid-teens revenue growth.

Thesis delta

No significant shift. The Q2 2026 call reaffirmed the strategic direction but provided no evidence of a breakthrough in profitability. The WAIT rating holds, as the market already discounts a successful restructuring without confirming results.